Adaptive Biotechnologies CSO sells 106K shares

Adaptive Biotechnologies Corp Chief Scientific Officer Harlan S. Robins reported open-market sales of company common stock.

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp Chief Scientific Officer Harlan S. Robins reported open-market sales of company common stock. He sold 100,000 shares on June 15, 2026 at a weighted-average price of $17.37 per share and 6,160 shares on June 16, 2026 at a weighted-average price of $18.01 per share.

All transactions were executed under a pre-arranged Rule 10b5-1 trading plan. After these sales, Robins directly holds 1,405,898 shares of Adaptive Biotechnologies common stock.

Insider Trade Summary 10b5-1

Net Seller: 106,160 shares

Net Sell 2 txns

Insider ROBINS HARLAN S

Role Chief Scientific Officer

Sold 106,160 shs ($1.85M)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,160	$18.01	$111K
Sale	Common Stock	100,000	$17.37	$1.74M

Holdings After Transaction: Common Stock — 1,405,898 shares (Direct)

Footnotes (3)

1. F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.
2. F2. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $17.14 to $17.96, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
3. F3. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $18.00 to $18.04, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

Key Figures

Total shares sold: 106,160 shares June 15 sale: 100,000 shares at $17.37/share June 16 sale: 6,160 shares at $18.01/share +4 more

7 metrics

Total shares sold 106,160 shares Open-market sales on June 15–16, 2026

June 15 sale 100,000 shares at $17.37/share Weighted-average price, open-market sale

June 16 sale 6,160 shares at $18.01/share Weighted-average price, open-market sale

Holdings after transactions 1,405,898 shares Direct ownership after June 16, 2026 sales

10b5-1 plan adoption date March 13, 2026 Plan governing reported sales

Price range June 15 $17.14–$17.96 Multiple transactions aggregated into weighted-average

Price range June 16 $18.00–$18.04 Multiple transactions aggregated into weighted-average

Key Terms

Rule 10b5-1 trading plan, weighted-average price, open-market sale

3 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted-average price financial

"The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions"

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Adaptive Biotechnologies (ADPT) report for Harlan S. Robins?

Adaptive Biotechnologies reported that Chief Scientific Officer Harlan S. Robins sold a total of 106,160 common shares in open-market transactions on June 15–16, 2026, according to a Form 4 insider trading report.

How many Adaptive Biotechnologies (ADPT) shares did the CSO sell and at what prices?

Harlan S. Robins sold 100,000 shares at a weighted-average price of $17.37 on June 15, 2026, and 6,160 shares at a weighted-average price of $18.01 on June 16, 2026, in open-market sales.

How many Adaptive Biotechnologies (ADPT) shares does Harlan S. Robins hold after these sales?

Following the reported transactions, Chief Scientific Officer Harlan S. Robins directly holds 1,405,898 shares of Adaptive Biotechnologies common stock, as disclosed in the Form 4 insider trading report filed with regulators.

Were the recent ADPT insider share sales by the CSO under a Rule 10b5-1 plan?

Yes. The Form 4 states the transactions were executed under a Rule 10b5-1 trading plan adopted by Harlan S. Robins on March 13, 2026, indicating the sales were pre-planned rather than discretionary.

What does weighted-average price mean in the ADPT insider sales disclosure?

Weighted-average price means the reported price per share reflects multiple trades within a range. For ADPT, sales on June 15 ranged from $17.14 to $17.96, and on June 16 from $18.00 to $18.04, aggregated into single average prices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 08:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROBINS HARLAN S

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE WASHINGTON 98109

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/15/2026		S(1)		100,000	D	$17.37(2)	1,412,058	D
Common Stock	06/16/2026		S(1)		6,160	D	$18.01(3)	1,405,898	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.

2. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $17.14 to $17.96, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

3. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $18.00 to $18.04, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

	/s/ Harlan S Robins by Kyle Piskel, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)